Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PRJ1-3024 |
Synonyms | |
Therapy Description |
PRJ1-3024 inhibits Hpk1 (Map4k1), which may reduce immunosuppression in the tumor microenvironment and result in induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PRJ1-3024 | PRJ1 3024|PRJ13024 | MAP4K1 Inhibitor 7 | PRJ1-3024 inhibits Hpk1 (Map4k1), which may reduce immunosuppression in the tumor microenvironment and result in induction of a cytotoxic T-lymphocyte (CTL) response against tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05159700 | Phase I | PRJ1-3024 | A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |